Chorioamnionitis and Culture-Confirmed, Early-Onset Neonatal Infections
BACKGROUND: Current guidelines for prevention of neonatal group B streptococcal disease recommend diagnostic evaluations and empirical antibiotic therapy for well-appearing, chorioamnionitis-exposed newborns. Some clinicians question these recommendations, citing the decline in early-onset group B streptococcal disease rates since widespread intrapartum antibiotic prophylaxis implementation and potential antibiotic risks. We aimed to determine whether chorioamnionitis-exposed newborns with culture-confirmed, early-onset infections can be asymptomatic at birth.
METHODS: Multicenter, prospective surveillance for early-onset neonatal infections was conducted during 2006–2009. Early-onset infection was defined as isolation of a pathogen from blood or cerebrospinal fluid collected ≤72 hours after birth. Maternal chorioamnionitis was defined by clinical diagnosis in the medical record or by histologic diagnosis by placental pathology. Hospital records of newborns with early-onset infections born to mothers with chorioamnionitis were reviewed retrospectively to determine symptom onset.
RESULTS: Early-onset infections were diagnosed in 389 of 396 586 live births, including 232 (60%) chorioamnionitis-exposed newborns. Records for 229 were reviewed; 29 (13%) had no documented symptoms within 6 hours of birth, including 21 (9%) who remained asymptomatic at 72 hours. Intrapartum antibiotic prophylaxis exposure did not differ significantly between asymptomatic and symptomatic infants (76% vs 69%; P = .52). Assuming complete guideline implementation, we estimated that 60 to 1400 newborns would receive diagnostic evaluations and antibiotics for each infected asymptomatic newborn, depending on chorioamnionitis prevalence.
CONCLUSIONS: Some infants born to mothers with chorioamnionitis may have no signs of sepsis at birth despite having culture-confirmed infections. Implementation of current clinical guidelines may result in early diagnosis, but large numbers of uninfected asymptomatic infants would be treated.
- CBC —
- complete blood count
- CDC —
- Centers for Disease Control and Prevention
- GBS —
- group B streptococcal
- IAP —
- intrapartum antibiotic prophylaxis
What’s Known on This Subject:
The Guidelines for Prevention of Perinatal Group B Streptococcal Disease recommend diagnostic evaluation and empirical antibiotic therapy for well-appearing infants born to mothers with chorioamnionitis. Some clinicians question this approach for term infants who are asymptomatic at birth.
What This Study Adds:
This study documents that some chorioamnionitis-exposed newborns with culture-confirmed, early-onset neonatal sepsis may be asymptomatic at birth or throughout the first 72 hours of age. However, current recommendations require treating large numbers of asymptomatic infants for each case identified.
Despite a substantial reduction in the rate of early-onset group B streptococcal (GBS) infection after widespread implementation of maternal intrapartum antibiotic prophylaxis (IAP) for GBS disease in the 1990s, neonatal sepsis remains an important cause of morbidity and mortality.1,2 Early recognition of signs of neonatal sepsis and prompt antibiotic therapy are thought to improve neonatal outcomes. Thus, empirical newborn antibiotic therapy in the context of known risk factors for neonatal sepsis, including chorioamnionitis, may reduce sepsis-related morbidity.3–5
Because associations between maternal chorioamnionitis and neonatal GBS disease have been documented in several observational studies,6–8 the Centers for Disease Control and Prevention (CDC) 2010 Guidelines for Prevention of Perinatal Group B Streptococcal Disease, endorsed by the American Academy of Pediatrics, the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists, recommend that well-appearing infants born to mothers with chorioamnionitis receive a limited diagnostic evaluation (a complete blood count [CBC] with differential and platelets and a blood culture at birth) and empirical antibiotic therapy.5,9–13 However, because the evidence behind these recommendations was limited to observational studies performed before widespread IAP use, some controversy surrounds the current recommendations. Some clinicians question, given widespread IAP use, whether diagnostic evaluations and empirical antibiotics are warranted for well-appearing term newborns exposed to chorioamnionitis.14 In addition, clinicians may be reluctant to separate well-appearing infants from their mothers, if necessary to provide empirical antibiotic therapy, given the potential negative impact on early bonding and initiation of breastfeeding, particularly if intrapartum antibiotics mitigate some of the risk of sepsis associated with chorioamnionitis. Furthermore, an association between prolonged empirical antibiotic use and mortality and morbidity has been suggested.15–17 In the absence of an elevated risk of sepsis, these concerns may outweigh potential benefits.
The proportion of chorioamnionitis-exposed newborns with invasive early-onset infections who are well appearing at birth has not been described. Because chorioamnionitis is uncommon, complicating 0.5% to 10% of deliveries, this question is difficult to explore at single hospitals, even large hospitals.18–20 With the use of data from a cohort of infants with early-onset infections identified through a multicenter research consortium, we aimed to determine whether newborns with culture-confirmed, early-onset infections born to mothers with chorioamnionitis can be asymptomatic at birth.
Prospective surveillance for early-onset neonatal infections was conducted by the Eunice Kennedy Shriver National Institute for Child Health and Human Development Neonatal Research Network among live-born infants of all gestational ages with birth weights >400 g who were delivered at 1 of 16 university-based centers from February 2006 through December 2009. The results have been reported previously.1 Detailed information was collected for infants with early-onset infections only. Hospital records of the cases born to mothers diagnosed with chorioamnionitis were retrospectively reviewed in 2013 to obtain more detailed information on the presence and timing of onset of clinical signs and symptoms of sepsis, timing of blood cultures and antibiotic therapy, and date and timing of CBC evaluation. Cases whose mothers had clinical chorioamnionitis, defined as a diagnosis of chorioamnionitis documented in the medical record or histologic chorioamnionitis documented by placental pathology, were included in the review. The institutional review board at each participating center approved the review of records; the CDC provided funding for the retrospective review, but data collection and analyses were performed by the study sites and RTI International.
Early-onset infections were defined by the isolation of a pathogen from blood or cerebrospinal fluid culture of specimens obtained within 72 hours of birth and antibiotic treatment of ≥5 days (or death at <5 days while receiving antibiotic therapy). During the prospective surveillance, cases were identified through review of patient, microbiology, and hospital epidemiology records. Coagulase-negative staphylococci, micrococci, propionibacteria, corynebacteria, or diphtheroids isolated from a single culture were considered contaminants, regardless of site determination of contamination status. Cultures that grew Bacillus species or that grew >1 organism were included unless the attending physician judged the culture to be contaminated and did not treat the infant or discontinued antibiotics before day 5 in a surviving infant.
During the surveillance study, maternal information was abstracted from labor and delivery records, including GBS screening results, risk factors for early-onset GBS disease, antibiotic use and clinical signs in the 72 hours before delivery, and documentation of clinical and histologic chorioamnionitis. Risk factors for early-onset GBS disease included a previous infant with GBS infection, GBS bacteriuria, delivery at <37 weeks’ gestation, rupture of membranes ≥18 hours before delivery, and intrapartum fever defined as a temperature ≥100.4°F (≥38.0°C) between the onset of labor and delivery. Maternal clinical signs included uterine or abdominal tenderness, foul-smelling vaginal discharge or amniotic fluid, tachycardia, or any temperature ≥100.4°F (≥38.0°C) in the 72 hours before delivery without regard to onset of labor. Information abstracted from the infant record included laboratory results, antibiotic therapy, severity of illness, and final status (death or survival to discharge, transfer, or 120 days).
For the current study, infants with early-onset infection and maternal chorioamnionitis were classified as symptomatic at birth if they had any signs of sepsis (Table 1) within 6 hours of birth. Infants with none of the reviewed signs or symptoms of sepsis within the first 6 hours were classified as asymptomatic at birth. Infants born before 37 weeks’ gestational age were classified as preterm.
Using the steps in Fig 1, we estimated the number of well-appearing infants, stratified by preterm versus term, born to women with chorioamnionitis who were potentially treated for each initially asymptomatic infant with culture-confirmed, early-onset infection assuming complete implementation of the Guidelines for Prevention of Perinatal Group B Streptococcal Disease. Because chorioamnionitis prevalence in the birth cohort was unknown, we used a range of prevalence rates from previous reports in our calculation.18–20 We rounded the estimates to 1 significant digit (if <100) or 2 significant digits to reflect imprecision of the estimates.
Statistical significance for unadjusted comparisons was determined by χ2 or Fisher’s exact test for categorical variables or the Kruskal-Wallis test for continuous variables. Analyses were performed by using SAS version 9.3 (SAS Institute, Cary, NC).
During the surveillance study, 389 cases of culture-confirmed, early-onset infection were identified among 396 586 live births at the 16 centers (0.98 cases per 1000 live births). Among infants infected, 232 (60%) were born to women with chorioamnionitis. Because medical records for 3 infants with maternal chorioamnionitis were unavailable for review, 229 were included in this analysis (Fig 2). Mothers of 110 (48%) infants were diagnosed with both clinical and histologic chorioamnionitis, 77 (34%) with histologic chorioamnionitis only, and 42 (18%) with clinical chorioamnionitis alone (placental pathology was performed but chorioamnionitis not diagnosed for 13 of 42 mothers; placental examination was not performed for 28 mothers; information missing for 1 mother) (Table 2). Risk factors for early-onset GBS infection were documented for 202 (89%) deliveries. At least 1 clinical sign consistent with chorioamnionitis was documented for the mothers of 162 (71%) infants within 72 hours before delivery, including 134 of 152 (88%) infants whose mothers had a clinical chorioamnionitis diagnosis. A majority of infants were born to mothers who received IAP, including 111 (75%) preterm and 48 (59%) term infants (P = .02). Penicillin, ampicillin, or cefazolin was included in the maternal regimens of 142 infants (62% of all infants, 89% of 159 whose mothers received IAP), as recommended by CDC GBS prevention guidelines. However, not all 142 infants were exposed to these drugs ≥4 hours before delivery as recommended (≥4 hours: 79 infants; <4 hours: 13 infants; exact timing could not be determined in 50 infants).
The majority of the 229 chorioamnionitis-exposed infants with early-onset infection were born at preterm gestation (preterm: 148 [65%]; term: 81 [35%]) (Fig 2, Table 3). Most preterm infants (135 of 148 [91%]) were born at 22–33 weeks’ gestation. A lumbar puncture was performed within 7 days after birth for 148 of 228 (65%) infants; term infants were more frequently assessed by lumbar puncture than preterm infants (66 of 81 [81%] vs 82 of 147 [56%]; P < .001; information was missing for 1 infant). Bacterial pathogens were isolated from blood for 219 of 229 (98%) infants; only 5 of 229 (2%) were diagnosed by growth from cerebrospinal fluid alone. Escherichia coli was the most frequently isolated organism overall (84 of 222 [38%] single-pathogen infections) and the most frequently isolated organism among preterm infants (75 of 144 [52%] single-pathogen infections). Group B Streptococcus was the most commonly isolated bacterial pathogen among term infants (47 of 78 [60%] single-pathogen infections). Consistent with group B Streptococcus prevention guidelines, a CBC was performed for a majority of infants within 6 hours of birth (191 of 225 [85%]; information missing for 4 infants), and most infants received antibiotic therapy within 6 hours (191 of 219 [87%]; information was missing for 10 infants). However, a CBC was more commonly performed for preterm infants than for term infants (141 of 146 [97%] vs 50 of 79 [63%]; P < .001), and a larger proportion of preterm infants received antibiotic therapy within 6 hours of birth (130 of 140 [93%] vs 61 of 79 [77%]; P < .001). Although 80 of 81 (99%) term infants survived to discharge, transfer, or 120 days, only 102 of 148 [69%] preterm infants survived to status (P < .001). The median length of hospital stay among survivors was 59 days longer for preterm infants (P < .001). Cause of death was recorded for 46 of 47 infants who died. Death was infection-related for 34 of 46 (74%) infants, including a term infant who died <9 hours after birth with an invasive E coli infection.
Timing of Signs and Symptoms of Early-Onset Infection
Signs or symptoms of sepsis were documented within 6 hours of birth for 200 (87%) of the 229 chorioamnionitis-exposed infants. No infants were considered symptomatic solely on the basis of CBC findings (ie, neutropenia or thrombocytopenia). All infants who died were symptomatic within 6 hours of birth. No signs or symptoms of sepsis were documented within 6 hours of birth for 29 (13%) infants, although 8 of 29 (28%) developed signs or symptoms of sepsis within 72 hours after birth (Fig 2). Selected characteristics of the 29 initially asymptomatic infants are depicted in Table 4. Although 23 of 29 (79%) were born at term, only 58 of 200 (29%) symptomatic infants were born at term (P < .001). Placental pathology was performed less often for deliveries of infants who were asymptomatic within 6 hours of birth compared with infants who were initially symptomatic (18 of 28 [64%] vs 182 of 200 [91%]; P < .001; information was missing for 1 infant). Correspondingly, clinical diagnoses of chorioamnionitis without histologic confirmation were more common among the initially asymptomatic infants than among the initially symptomatic infants (12 of 29 [41%] vs 30 of 200 [15%]; P = .002). Group B Streptococcus was the most common pathogen among initially asymptomatic infants (18 of 29 [62%]), whereas E coli was the most common pathogen among symptomatic infants (83 of 193 [43%] single-pathogen infections).
The proportion of initially asymptomatic infants whose mothers received intrapartum antibiotics was not significantly different than the proportion for symptomatic infants (22 of 29 [76%] vs 137 of 200 [69%]; P = .52). However, the proportions of asymptomatic and symptomatic term infants whose mothers received intrapartum antibiotics differed (18 of 23 [78%] vs 30 of 58 [52%]; P = .04). A CBC was obtained for a smaller proportion of asymptomatic infants than of symptomatic infants (12 of 29 [41%] vs 179 of 196 [91%]; P < .001), and fewer asymptomatic infants received antibiotics within 6 hours of birth (17 of 28 [61%] vs 173 of 191 [91%]; P < .001). Whether born preterm or at term, a smaller proportion of asymptomatic infants had a CBC performed (preterm: 5 of 6 [83%] vs 136 of 140 [97%] infants; P = .19; term: 7 of 23 [30%] vs 43 of 56 [77%] infants; P < .001) or received antibiotics within 6 hours of birth (preterm: 3 of 6 [50%] vs 127 of 134 [95%] infants; P = .005; term: 15 of 23 [65%] vs 46 of 56 [82%] infants; P = .14). None of the initially asymptomatic infants received mechanical ventilation compared with 140 of 200 (70%) symptomatic infants.
Delivery at <37 weeks’ gestation (P < .001), rupture of membranes ≥18 hours (P = .04), and uterine or abdominal tenderness (P = .03) were more commonly documented for mothers of infants who were symptomatic than for mothers whose infants were initially asymptomatic (Table 5). In contrast, intrapartum fever (P = .01) and fever in the 72 hours before delivery (P < .001) were more common for women with chorioamnionitis whose infants were initially asymptomatic.
Number of Infants Treated for Each Well-Appearing Infant With Early-Onset Infection
The total birth cohort may have included between 1983 and 39 659 infants whose mothers had chorioamnionitis depending on chorioamnionitis prevalence (Table 6). Assuming complete implementation of current guidelines for the prevention of GBS disease, we estimated that 60 to 1400 well-appearing newborns born to mothers with chorioamnionitis might undergo diagnostic evaluation and receive empirical antibiotics for each initially asymptomatic infant with culture-confirmed, early-onset infection. Estimates calculated for term and preterm infants separately were even higher (Table 6).
In this cohort, although the majority of infants with culture-confirmed, early-onset infection born to women with chorioamnionitis displayed signs and/or symptoms of infection within 6 hours of birth, 29 of 229 (13%) were initially asymptomatic and 21 (9%) remained asymptomatic during the first 72 hours after birth. The majority of these initially asymptomatic infants were born at term gestation, and group B Streptococcus was the most common pathogen isolated. Perhaps because most initially asymptomatic infants were born at term, they were less likely than symptomatic infants to receive empirical antibiotics or to be evaluated with a CBC, as recommended by CDC guidelines for prevention of GBS disease. Nonetheless, no deaths occurred among initially asymptomatic infants.
E coli was the most common etiology of early-onset infection among all infants born to mothers with chorioamnionitis. This finding is likely because infants born to mothers with chorioamnionitis were more often preterm and E coli infections are strongly associated with birth at <34 weeks’ gestational age.1,2 Preterm infants often have nonspecific signs and symptoms consistent with both sepsis and prematurity.21 Even in the absence of chorioamnionitis, the risk of early-onset infections among preterm infants is much higher than among term infants.1 Therefore, although our estimates of the number of asymptomatic preterm infants treated for each infant with early-onset infection are high, diagnostic evaluations and empirical treatment of these asymptomatic infants may be justified in the context of the higher risk conferred by prematurity alone. Although many clinicians perform diagnostic evaluations and initiate empirical antibiotic therapy for preterm infants, the optimal management of term, asymptomatic, chorioamnionitis-exposed infants is more controversial.
Despite the tremendous impact of IAP to reduce the vertical transmission of group B Streptococcus from colonized at-risk mothers, group B Streptococcus remains the leading infectious cause of neonatal morbidity and mortality.1,2 Although the risk of neonatal GBS disease increases with preterm delivery, the majority of infants with early-onset GBS disease are delivered at term, because most infants are born at term. Perhaps because the mothers of most infants in the study had risk factors for early-onset GBS disease, a majority received intrapartum antibiotics. In the context of chorioamnionitis, it is possible that routine IAP masks symptoms of infection in neonates born to women who received antibiotics. This masking of symptoms may explain our finding that a higher proportion of initially asymptomatic term infants had mothers who received intrapartum antibiotics than did symptomatic term infants. This possibility may also explain our observation that maternal fever and intrapartum fever (both indications for intrapartum antibiotics) were more common among deliveries of asymptomatic infants. Nonetheless, the findings that 29 of 229 (13%) infected infants born to women with chorioamnionitis were asymptomatic within 6 hours of birth and 18 of 29 (62%) of these infants were infected with group B Streptococcus suggest that current recommendations with regard to evaluation and empirical antibiotic therapy for well-appearing infants born to mothers with chorioamnionitis may result in earlier diagnosis and treatment of early-onset infections. However, the implementation of these guidelines may result in diagnostic testing and empirical antibiotics for a substantial number of healthy, uninfected, chorioamnionitis-exposed infants. The precise ratio of well-appearing, chorioamnionitis-exposed infants potentially evaluated and treated for each initially asymptomatic infant with early-onset infection varies widely depending on the prevalence of chorioamnionitis. Additional prospective characterization of population-level chorioamnionitis prevalence rates may inform future guideline development.
This study has limitations. We had data only for infants with culture-confirmed, early-onset infections. We were therefore unable to determine the prevalence of maternal chorioamnionitis in the cohort and have no information on the number of chorioamnionitis-exposed infants with negative cultures who may have been well appearing or symptomatic at birth. To make our classification of infants with culture-confirmed, early-onset infections as sensitive as possible, we considered infants with any nonspecific clinical finding associated with sepsis to be symptomatic. The extent to which these factors contributed to an over- or underestimate of the proportion of chorioamnionitis-exposed infants in the cohort who were asymptomatic within 6 hours of birth is unknown. With case data only, we were unable to assess whether empirical therapy given to chorioamnionitis-exposed, well-appearing infants reduces the risk of severe disease compared with a “wait and see” approach. By including infants in our review whose mothers had a diagnosis of chorioamnionitis in the medical record without documentation of specific clinical signs (eg, fever, uterine tenderness), we may have included some infants who were not exposed to chorioamnionitis. Nonetheless, chorioamnionitis is a clinical diagnosis often based on nonspecific signs; therefore, obstetric providers’ diagnoses guide neonatal management. The inclusion of these infants was important for estimating the number of asymptomatic infants treated for each infant with early-onset infection. Furthermore, we relied solely on retrospective data abstracted from the medical records during 2013 for information about clinical presentations during 2006–2009. Therefore, our findings should be considered along with changes in neonatal care practices that have occurred during the interim period. In addition, real-time discussions with providers may have informed verification that infants were asymptomatic and determinations of whether unusual organisms represented contaminants. Nonetheless, pathogens typically associated with neonatal sepsis were isolated from the majority of infants, including those who were initially asymptomatic, giving us confidence in our retrospective assessment.
The majority (60%) of infants with early-onset infections identified in the multicenter parent study were born to women with chorioamnionitis. We found that a significant proportion (13%) of these chorioamnionitis-exposed infants were initially asymptomatic. Even with widespread IAP use and declining early-onset GBS infection rates, efforts to evaluate and provide empirical treatment of initially well-appearing infants whose mothers had chorioamnionitis may result in timely early-onset infection diagnoses and prompt therapy for affected infants. However, substantial numbers of asymptomatic infants born to women with chorioamnionitis would potentially require treatment under the current guidelines. Our findings should prompt further investigation into chorioamnionitis prevalence rates to better quantify numbers needed to treat so that the benefit of early diagnosis can be more precisely considered along with the hazards of empirical antibiotic use in unaffected, term infants.
Participating Neonatal Research Network (NRN) sites collected data and transmitted them to RTI International, the data coordinating center (DCC) for the network, which stored, managed, and analyzed the data for this study. On behalf of the NRN, Dr Abhik Das (DCC Principal Investigator) and Ms Nellie I. Hansen (DCC Statistician) had full access to all of the data in the study and, with the NRN Center principal investigators, take responsibility for the integrity of the data and accuracy of the data analysis.
The original surveillance study was supported, in part, by PHS grant UL1 RR0025008 from the Clinical and Translational Science Award Program, National Institutes of Health, National Center for Research Resources.
The following investigators, in addition to those listed as authors, participated in this study: NRN Steering Committee Chair: Michael S. Caplan, MD: University of Chicago, Pritzker School of Medicine (2006–2011). Abbot R. Laptook, MD, Angellita M. Hensman, MS RNC-NIC BSN, William Oh, MD:Alpert Medical School of Brown University and Women & Infants Hospital of Rhode Island (General Clinical Research Center (GCRC) Grant: U10 HD27904). Michelle C. Walsh, MD MS; Avroy A. Fanaroff, MD, Nancy S. Newman, RN:
Case Western Reserve University, Rainbow Babies & Children's Hospital (GCRC U10 HD21364, M01 RR80). Centers for Disease Control and Prevention (Interagency Agreement 05FED32885-00). Kurt Schibler, MD, Edward F. Donovan, MD, Cathy Grisby, BSN, CCRC, Barbara Alexander, RN, Kate Bridges, MD, Jody Hessling, RN, Holly L. Mincey, RN, BSN: Cincinnati Children's Hospital Medical Center, University of Cincinnati Medical Center, and Good Samaritan Hospital (U10 HD27853, M01 RR8084). C. Michael Cotten, MD, MHS, Kimberley A. Fisher, PhD, FNP-BC, IBCLC, Kathy J. Auten, MSHS, Katherine A. Foy, RN, Sandra Grimes, RN, BSN: Duke University School of Medicine, University Hospital, and Duke Regional Hospital (GCRC U10 HD40492, UL1 TR1117, M01 RR30).David P. Carlton, MD, Yvonne C. Loggins, RN, BSN: Emory University, Children’s Healthcare of Atlanta, Grady Memorial Hospital, and Emory University Hospital Midtown (U10 HD27851, M01 RR39). Stephanie Wilson Archer, MA: Eunice Kennedy Shriver National Institute of Child Health and Human Development. Leslie Dawn Wilson, BSN, CCRC, Dianne E. Herron, RN, Lucy C. Miller, RN, BSN, CCRC: Indiana University, University Hospital, Methodist Hospital, Riley Hospital for Children at Indiana University Health, and Eskenazi Health (GCRC U10 HD27856, M01 RR750). W. Kenneth Poole, PhD (deceased), Kristin M. Zaterka-Baxter, RN, BSN, CCRP, Margaret Crawford, BS, CCRP, Jeanette O’Donnell Auman, BS, Carolyn M. Petrie Huitema, MS, CCRP: RTI International (GCRC U10 HD36790). David K. Stevenson, MD, M. Bethany Ball, BS, CCRC, Marian M. Adams, MD, Magdy Ismail, MD, MPH, Andrew W. Palmquist, RN, BSN, Melinda S. Proud, RCP: Stanford University, Dominican Hospital, El Camino Hospital, and Lucile Packard Children's Hospital (GCRC U10 HD27880, M01 RR70). Brenda L. MacKinnon, RNC, Ellen Nylen, RN, BSN: Tufts Medical Center, Floating Hospital for Children (GCRC U10 HD53119, M01 RR54). Waldemar A. Carlo, MD, Namasivayam Ambalavanan, MD, Monica V. Collins, RN, BSN, MAEd, Shirley S. Cosby, RN, BSN: University of Alabama at Birmingham Health System and Children’s Hospital of Alabama (GCRC U10 HD34216, M01 RR32). Edward F. Bell, MD, John A. Widness, MD, Karen J. Johnson, RN, BSN: University of Iowa (GCRC U10 HD53109, M01 RR59). Kristi L. Watterberg, MD, Conra Backstrom Lacy, RN, Rebecca A. Montman, BSN, RNC: University of New Mexico Health Sciences Center (U10 HD53089, M01 RR997). Charles R. Rosenfeld, MD, Luc P. Brion, MD, Walid A. Salhab, MD, Alicia Guzman, Gaynelle Hensley, RN, Melissa H. Leps, RN, Nancy A. Miller, RN, Diane M. Vasil, RNC-NIC: University of Texas Southwestern Medical Center at Dallas, Parkland Health & Hospital System, and Children's Medical Center Dallas (GCRC U10 HD40689, M01 RR633). Kathleen A. Kennedy, MD, MPH, Jon E. Tyson, MD, MPH, Julie Arldt-McAlister, RN, BSN, Georgia E. McDavid, RN, Sharon L. Wright, MT (ASCP): University of Texas Health Science Center at Houston Medical School and Children's Memorial Hermann Hospital (GCRC U10 HD21373). Bradley A. Yoder, MD, Karen A. Osborne, RN, BSN, CCRC, Karie Bird, RN, BSN, Jennifer J. Jensen, RN, BSN, Cynthia Spencer, RNC, Kimberlee Weaver-Lewis, RN, BSN: University of Utah Medical Center, Intermountain Medical Center, LDS Hospital, and Primary Children's Medical Center (GCRC U10 HD53124, M01 RR64). Seetha Shankaran, MD, Rebecca Bara, RN, BSN, Mary E. Johnson, RN, BSN, Elizabeth Billian, RN, MBA: Wayne State University, University of Michigan, Hutzel Women’s Hospital, and Children’s Hospital of Michigan (U10 HD21385). Richard A. Ehrenkranz, MD, Harris C. Jacobs, MD, Monica Konstantino, RN, BSN, Patricia Cervone, RN, JoAnn Poulsen, RN, Janet Taft, RN, BSN: Yale University, Yale–New Haven Children’s Hospital, and Bridgeport Hospital (U10 HD27871, M01 RR125, UL1 TR142).
We thank our medical and nursing colleagues and the infants and their parents who agreed to take part in this study.
- Accepted October 14, 2015.
- Address correspondence to Jonathan M. Wortham, MD, Division of Tuberculosis Elimination, 1600 Clifton Rd Northeast, Mailstop E-10, Atlanta, GA 30333. E-mail:
Although Eunice Kennedy Shriver National Institute of Child Health and Human Development and Centers for Disease Control and Prevention staff had input into the study design, conduct, analysis, and manuscript drafting, the content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Centers for Disease Control and Prevention.
FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.
FUNDING: This study was supported by funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Centers for Disease Control and Prevention. Funded by the National Institutes of Health (NIH).
POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.
- Stoll BJ,
- Hansen NI,
- Sánchez PJ, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network
- Schuchat A,
- Deaver-Robinson K,
- Plikaytis BD,
- Zangwill KM,
- Mohle-Boetani J,
- Wenger JD; Active Surveillance Study Group
- Verani JR,
- McGee L,
- Schrag SJ
- Velaphi S,
- Siegel JD,
- Wendel GD Jr,
- Cushion N,
- Eid WM,
- Sánchez PJ
- Verani JR,
- Schrag SJ
- Polin RA; Committee on Fetus and Newborn
- Schuchat A,
- Wenger JD
- Schuchat A,
- Zywicki SS,
- Dinsmoor MJ, et al
- Clark RH,
- Bloom BT,
- Spitzer AR,
- Gerstmann DR
- Cotten CM,
- Taylor S,
- Stoll B, et al; NICHD Neonatal Research Network
- Cacho N,
- Neu J
- Copyright © 2016 by the American Academy of Pediatrics